Totaligent, Inc. (OTC: TGNT) announced on February 25 that it had executed a binding Letter of Intent (LOI) with GloMed Solutions Limited Liability Company on February 22, 2026. The LOI establishes a joint venture that will integrate Totaligent’s recently acquired Aetherium Medical platform into GloMed’s operations and grants Totaligent a binding call option to acquire GloMed outright within a year, contingent on a PCAOB‑compliant audit and regulatory approvals.
GloMed currently reports about $10 million in annual revenue and $1 million in free cash flow, a high‑value target for Totaligent, whose own financials show a minimal recent revenue stream and a current ratio of 0.04, indicating liquidity challenges. The partnership is designed to leverage Totaligent’s precision marketing capabilities to target AI‑biotech innovators and APAC clinics, accelerating the commercialization of advanced biologics and expanding the company’s presence in the rapidly growing medical tourism market.
The joint venture will be governed by a three‑member board, all appointed by Totaligent: Edward DeFeudis, Don Heath (CEO of GloMed), and Ivan Klarich. The binding call option gives Totaligent the right to acquire GloMed fully, subject to due diligence and the completion of a PCAOB audit, providing a phased approach to integration and risk mitigation.
Targeted closing for the joint venture is around March 22, 2026, approximately four weeks after the LOI execution. The deal will be funded through Totaligent’s standby equity purchase agreement, which will cover the cash portion of the transaction and ongoing operational needs.
This transaction follows Totaligent’s recent acquisition of the Aetherium Medical team, intellectual property, and platform assets on February 11, 2026, making the joint venture a natural extension of its strategic growth plan. The deal is material and could significantly alter Totaligent’s revenue profile, positioning it for accelerated growth in the APAC medical aesthetics and biologics market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.